Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy

NCT01360554 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01360554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01360554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
June 16, 2011
Completion date
September 14, 2015
Enrollment
878 (actual)
Sites
224

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer